TREM-1 and its potential ligands in non-infectious diseases: from biology to clinical perspectives

Triggering receptor expressed on myeloid cells-1 (TREM-1) is expressed on the majority of innate immune cells and to a lesser extent on parenchymal cells. Upon activation, TREM-1 can directly amplify an inflammatory response. Although it was initially demonstrated that TREM-1 was predominantly assoc...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Pharmacology & therapeutics (Oxford) Ročník 177; s. 81 - 95
Hlavní autoři:	Tammaro, Alessandra, Derive, Marc, Gibot, Sebastien, Leemans, Jaklien C., Florquin, Sandrine, Dessing, Mark C.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England 01.09.2017
Témata:	Animals Humans Inflammation - drug therapy Inflammation - metabolism Ligands Signal Transduction Triggering Receptor Expressed on Myeloid Cells-1 - antagonists & inhibitors Triggering Receptor Expressed on Myeloid Cells-1 - genetics Triggering Receptor Expressed on Myeloid Cells-1 - metabolism TREM-1 ligands TREM-1 inhibitors Non-infectious inflammatory diseases Triggering receptor expressed on myeloid cells-1 TLR/NLR pathway
ISSN:	0163-7258, 1879-016X, 1879-016X
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Triggering receptor expressed on myeloid cells-1 (TREM-1) is expressed on the majority of innate immune cells and to a lesser extent on parenchymal cells. Upon activation, TREM-1 can directly amplify an inflammatory response. Although it was initially demonstrated that TREM-1 was predominantly associated with infectious diseases, recent evidences shed new light into its role in sterile inflammatory diseases. Indeed, TREM-1 receptor and its signaling pathways contribute to the pathology of several non-infectious acute and chronic inflammatory diseases, including atherosclerosis, ischemia reperfusion-induced tissue injury, colitis, fibrosis and cancer. This review, aims to give an extensive overview of TREM-1 in non-infectious diseases, with the focus on the therapeutic potential of TREM-1 intervention strategies herein. In addition, we provide the reader with a functional enrichment analysis of TREM-1 signaling pathway and potential TREM-1 ligands in these diseases, obtained via in silico approach. We discuss pre-clinical studies which show that TREM-1 inhibition, via synthetic soluble TREM-1 protein mimickers, is effective in treating (preventing) specific inflammatory disorders, without significant effects on antibacterial response. Further research aimed at identifying specific TREM-1 ligands, in different inflammatory disorders, is required to further unravel the role of this receptor, and explore new avenues to modulate its function.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ISSN:	0163-7258 1879-016X 1879-016X
DOI:	10.1016/j.pharmthera.2017.02.043